The Food and Drug Administration has weathered nine months of unprecedented turbulence in 2025, yet drug approval numbers tell a surprisingly stable story. Despite the exodus of senior leadership, staffing reductions, and high-profile controversies, the agency has maintained approval rates consistent with recent years—a testament to institutional resilience that offers important lessons for companies operating […]